北京商报讯（记者 王寅浩 宋雨盈）1月21日，甘李药业发布2025年业绩预告，公司预计2025年实现归属 于母公司所有者的净利润为11亿—12亿元，同比增加78.96%—95.23%。预计实现归属于母公司所有者 的扣除非经常性损益的净利润为7亿—8亿元，同比增加62.63%到85.86%。 ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-007 甘李药业股份有限公司 北京旭特宏达科技有限公司（以下称"旭特宏达"）持有甘李药业股份 有限公司（以下简称"公司"）无限售条件流通股 32,073,734 股，占公司总股本 的5.37%。公司于2026年1月21日收到通知，旭特宏达已于近日办理完毕700,000 股公司股份的解押登记手续。本次股份解除质押后，旭特宏达累计质押公司股份 数量为 22,710,000 股，占其持股数量的 70.81%，占公司总股本的 3.80%。 控股股东、实际控制人甘忠如先生及其控制的北京旭特宏达科技有限公 司（以下简称"旭特宏达"）合计持有公司股份 237,717,491 股，占公司总股本 的 39.80%。本次股份解除质押后，甘忠如先生及旭特宏达累计质押公司股份数 量为 22,710,000 股，占其持股数量的 9.55%，占公司总股本的 3.80%。 关于公司持股 5%以上股东部分股份解押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 股东名称 ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-008 甘李药业股份有限公司 关于完成工商登记信息变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 统一社会信用代码：91110000102382249M 类型：股份有限公司（外商投资、上市） 住所：北京市通州区漷县镇南凤西一路 8 号 法定代表人：陈伟 注册资本：人民币 59730.4969 万元 2025 年 9 月 8 日，甘李药业股份有限公司（以下简称"公司"）已完成自 2024 年 9 月 5 日至 2025 年 9 月 4 日累计通过回购专用证券账户以集中竞价交易 方式实施回购股份 3,540,021 股的回购注销。回购用途为"用于减少注册资本"。 回购注销完成后，公司总股本由 601,065,290 股变更为 597,525,269 股，注册资本 由 601,065,290 元变更为 597,525,269 元。具体内容详见公司在上海证券交易所网 站（www.sse.com.cn）披露的《关于股份回购实施结果暨股份变动的公告》（公 告编号： ...

甘李药业股份有限公司 2025 年年度业绩预增公告 证券代码：603087 证券简称：甘李药业 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1. 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 2. 甘李药业股份有限公司（以下简称"公司"）预计 2025 年年度实现归属于 母公司所有者的净利润为 11.00 亿元到 12.00 亿元，与上年同期（法定披露数据） 相比，将增加 4.85 亿元到 5.85 亿元，同比增加 78.96%到 95.23%。 3. 公司预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净 利润为 7.00 亿元至 8.00 亿元，与上年同期（法定披露数据）相比，将增加 2.70 亿元到 3.70 亿元，同比增加 62.63%到 85.86%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1. 经财务部门初步测算，预计 2025 ...

人民财讯1月21日电，甘李药业（603087）1月21日公告，预计2025年度实现归属于母公司所有者的净利 润为11亿元到12亿元，同比增加78.96%到95.23%。2025年度，公司预计归属于母公司所有者的净利润 较去年同期实现大幅增长，主要受益于国内外收入增长、股权转让收益。 ...

每经AI快讯，1月21日，甘李药业（603087）(603087.SH)发布2025年度业绩预告，预计归属于上市公司 股东的净利润为11.00亿元到12.00亿元，与上年同期相比增加78.96%到95.23%。报告期内，公司国内外 收入增长，胰岛素制剂产品销量与销售额大幅上升，国际化战略推进取得成效，同时因转让甘甘江苏 55%股权获得投资收益，带动净利润增长。 ...

甘李药业公告称，持股5.37%的股东旭特宏达于2026年1月20日办理完毕70万股公司股份解押手续，占 其所持股份比例2.18%，占公司总股本比例0.12%。本次解押后，旭特宏达累计质押公司股份2271万 股，占其持股数量的70.81%，占公司总股本的3.80%。控股股东甘忠如及其控制的旭特宏达合计持有公 司39.80%股份，累计质押股份占其持股数的9.55%，占公司总股本的3.80%。旭特宏达资信良好，股份 质押风险可控，对公司经营无实质影响。 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Summary of the Conference Call for Ganli Pharmaceutical (603087.SH) Company Overview - Ganli Pharmaceutical has received marketing approvals for its insulin products in the European Union and Ethiopia on January 14 and 15 [1][1]. - The company has been exporting insulin analog raw materials and formulations for over ten years, with products approved in more than 20 countries [3][3]. Key Points and Arguments Revenue and Profit Forecasts - The revenue and net profit forecasts for 2026E-2027E have been raised, and a new forecast for 2028E has been introduced [1][1]. - The target price has been increased from 73 RMB to 83 RMB, maintaining a "Buy" rating [2][2]. Global Expansion - Brazil is highlighted as the most significant overseas market, with a 10-year agreement signed with a local partner, ensuring a minimum cumulative income of no less than 3 billion RMB [3][3]. - The company is expanding into high-potential emerging markets such as Mexico, Argentina, India, and Turkey [4][4]. - In developed markets, the company has received EU approval for its insulin products, with others currently under regulatory review [4][4]. Clinical Pipeline Updates - The advanced pipeline includes GLP-1 drug GZR18, weekly insulin GZR4, and next-generation premixed insulin GZR101 [5][5]. - GZR4 is expected to enter Phase III clinical trials in 2025, with improved pricing and commercialization visibility [1][1]. Advantages and Collaborations - The core advantage of the GLP-1 drug is its lower dosing frequency, with positive data from a Phase II weight loss trial [6][6]. - The company collaborates with Sandoz for the commercialization of diabetes products, estimated to follow a 50/50 revenue-sharing model [4][4]. Additional Important Information - The company has strict quality control standards and has obtained EU GMP certification, contributing to its ongoing overseas expansion [4][4]. - The introduction of a monthly dosing regimen for GZR18 is in Phase III trials, which could enhance patient convenience and compliance [6][6].

Group 1 - The core viewpoint of the articles indicates a mixed performance in the medical and healthcare sector, with the China Medical and Medical Device Innovation Index experiencing a decline of 0.85% as of January 20, 2026, while certain stocks like Xinhecheng and Xingqi Eye Medicine showed gains [1] - The medical innovation ETF saw a decrease of 0.80%, with the latest price at 0.37 yuan, reflecting the overall market sentiment [1] - The brain-computer interface concept is gaining traction, supported by a significant investment of over 730 billion yuan in technology loans by the China Export-Import Bank, focusing on AI, brain-computer interfaces, humanoid robots, and high-end instruments [1] Group 2 - According to J.P. Morgan's conference, over 20 Chinese companies participated, highlighting the growing global interest in domestic innovative drugs and medical devices, which is expected to boost industry sentiment [1] - The China Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2] - Recent data shows a net inflow of 1.8727 million yuan into the medical innovation ETF, with a total of 59.7643 million yuan over the past five trading days, indicating a positive trend in investor interest [2]